⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL232815 | 1.00 | — | — | |
| SCHEMBL894123 | 1.00 | — | — | |
| Ammonia Solution, Strong SCHEMBL29073423 | 0.97 | KDM4E (0.38) | — | |
| Hydrochloric Acid SCHEMBL17202017 | 0.97 | KDM4E (0.42) | — | |
| Hydrochloric Acid SCHEMBL17202018 | 0.97 | KDM4E (0.42) | — | |
| Hydrochloric Acid SCHEMBL21817810 | 0.97 | KDM4E (0.42) | — | |
| SCHEMBL2246580 | 0.92 | CYP2D6 (0.34) | — | |
| SCHEMBL12100332 | 0.92 | CYP2D6 (0.34) | — | |
| SCHEMBL1036841 | 0.92 | CYP2D6 (0.34) | — | |
| SCHEMBL1110677 | 0.90 | CYP2D6 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 353 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3802500-B1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | CRINETICS PHARMACEUTICALS INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260069571-A1 | DDR1 AND DDR2 INHIBITORS FOR THE TREATEMENT OF CANCER AND FIBROTIC DISEASES | REDX PHARMA PLC (GB) | 2026-03-12 | — | — | US | disclosed |
| US-12558341-B2 | Oral complement factor D inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4676923-A1 | BIARYLAMIDE DERIVATIVES AND THEIR USE AS PKMYT1 INHIBITORS | Cancer Research Technology Limited (GB) | 2026-01-14 | — | — | EP | disclosed |
| EP-4387963-B1 | PHENYL- AND PYRIDOPYRAZOLE DERIVATIVES AS INHIBITORS OF DDR1 | REDX PHARMA LTD (GB) | 2025-12-24 | — | — | EP | disclosed |
| EP-4426688-B1 | DDR1 AND DDR2 INHIBITORS FOR THE TREATEMENT OF CANCER AND FIBROTIC DISEASES | REDX PHARMA LTD (GB) | 2025-12-03 | — | — | EP | disclosed |
| US-12479825-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2025-11-25 | — | — | US | disclosed |
| US-12479828-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2025-11-25 | — | — | US | disclosed |
| EP-4634161-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Tenvie Therapeutics Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250214976-A1 | GPR35 MODULATORS AND USES THEREOF | CROSSIGNAL THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20060142362-A1 | Pyrazoles, triazoles, or tetrazoles substituted with an aryl- or heteroarylcarbonylamino group and an aminocarbonylmethyl group: 5-chloro-thiophene-2-carboxylic acid (1-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenylcarbamoyl]-methyl}-1H-[1,2,4]triazol-3-yl)-amide; improved selectivity towards thrombin | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | US | disclosed |
| WO-2006023396-A2 | VLA-4 ANTAGONISTS | MERCK & CO., INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| US-5605926-A | PROPHYLAXIS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-02-25 | — | — | US | disclosed |
| EP-0744954-A1 | CATHEPSIN D IS AN AMYLOIDOGENIC PROTEASE IN ALZHEIMER'S DISEASE | Bayer Corporation (US) | 1996-12-04 | — | — | EP | disclosed |
| EP-0694076-A1 | CATHEPSIN D IS AN AMYLOIDOGENIC PROTEASE IN ALZHEIMER'S DISEASE | Bayer Corporation (US) | 1996-01-31 | — | — | EP | disclosed |
| EP-0694076-A4 | CATHEPSIN D IS AN AMYLOIDOGENIC PROTEASE IN ALZHEIMER'S DISEASE | BAYER AG (US) | 1995-12-13 | — | — | EP | disclosed |
| US-5430151-A | Treatment of aids, pneumonia, caprine arthritis encephalitis, leukemia and immmunodeficiency | BAYER AKTIENGESELLSCHAFT (DE) | 1995-07-04 | — | — | US | disclosed |
| WO-1995013084-A1 | CATHEPSIN D IS AN AMYLOIDOGENIC PROTEASE IN ALZHEIMER'S DISEASE | MILES INC. (US) | 1995-05-18 | — | — | WO | disclosed |
| WO-1994013319-A1 | CATHEPSIN D IS AN AMYLOIDOGENIC PROTEASE IN ALZHEIMER'S DISEASE | MILES INC. (US) | 1994-06-23 | — | — | WO | disclosed |
| EP-0528242-A2 | Trifluoromethyl containing pseudopeptides | BAYER AG (DE) | 1993-02-24 | — | — | EP | disclosed |